ESC: Finerenone Demonstrates CVD Benefit in FIGARO-DKD
Benefit driven by 29% relative reduction in heart failure hospitalization SGLT2 inhibitors were...
Dec 30, 2021
Benefit driven by 29% relative reduction in heart failure hospitalization SGLT2 inhibitors were...
Sep 8, 2021
A novel analysis of DAPA-HF investigated the efficacy of dapagliflozin on ventricular arrhythmia (VA), resuscitated cardiac arrest (RCA), and sudden death. The results showed a significantly reduced likelihood for the composite...
Sep 8, 2021
The GUIDE-HF trial, presented in a Hot Line Session and simultaneously published in The Lancet, showed benefits of hemodynamic-guided heart failure (HF) management with an implantable device in reducing HF hospitalization [1,2]....
Sep 8, 2021
An American trial investigated the potential of valsartan in slowing the course of disease in hypertrophic cardiomyopathy (HCM). The results showed a significantly positive influence on relative cardiac remodeling in the...
Sep 7, 2021
The randomized controlled STEP trial revealed that lowering the systolic blood pressure (SBP) to below 130 mmHg in patients over 60 years led to a 26% reduction of adverse cardiovascular (CV) events [1]. A target SBP below 130...
Sep 6, 2021
EMPEROR-Preserved proved to be a landmark trial in heart failure research. It demonstrated a clinically meaningful benefit of 21% reduction in the primary composite outcome as well as positive results in secondary outcomes with...
Sep 6, 2021
SSaSS trial finds mortality benefit for salt substitute vs salt Reducing the use of discretionary...
Sep 2, 2021
STEP results demonstrate clinical benefit when systolic drops below 130 mmHg An intensive blood...
Aug 30, 2021
Clinically meaningful benefit seen in patients with EF >40% Among symptomatic heart failure...
Aug 25, 2021
Investigators used a Web-based recording system, as well as face-to-face regional benchmark analysis and educational meetings, in the BLITZ-HF prospective study to evaluate and improve adherence to heart failure (HF)...